Scholarlink

<p>Bilirubin, a heme-derived metabolite with pronounced bioactivity, exhibits significant potential for pharmaceutical applications. This study developed a recombinant <i>Escherichia coli</i>-based biliverdin biotransformation system, enabling efficient bilirubin synthesis via heterologous expression of a novel biliverdin reductase (BvdR’, XP_032760038.1) from <i>Rattus norvegicus</i> and a glucose dehydrogenase (GDH) from <i>Priestia megaterium</i>. Under optimized conditions (520&#xa0;mg/L biliverdin, pH 7.5, 37&#xa0;°C), the system achieved a biliverdin conversion rate of 99.2% and a bilirubin yield of 89.9%. The integration of an NADPH in situ regeneration system significantly reduced synthesis costs, providing a novel strategy for scalable bilirubin production.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recombinant Escherichia coli biotransformation of biliverdin to synthesize bilirubin

  • 期刊论文

  • 发表日期：

    2025年8月26日

查看全文
  • Yue Zhang,
  • Haoni Luan,
  • Wenhan Qiu,
  • Wei Xu,
  • Wei Feng,
  • Fei Wang,
  • Peng Song

摘要

Bilirubin, a heme-derived metabolite with pronounced bioactivity, exhibits significant potential for pharmaceutical applications. This study developed a recombinant Escherichia coli-based biliverdin biotransformation system, enabling efficient bilirubin synthesis via heterologous expression of a novel biliverdin reductase (BvdR’, XP_032760038.1) from Rattus norvegicus and a glucose dehydrogenase (GDH) from Priestia megaterium. Under optimized conditions (520 mg/L biliverdin, pH 7.5, 37 °C), the system achieved a biliverdin conversion rate of 99.2% and a bilirubin yield of 89.9%. The integration of an NADPH in situ regeneration system significantly reduced synthesis costs, providing a novel strategy for scalable bilirubin production.